Rocket Pharmaceuticals, Inc. (RCKTW) — SEC Filings
Rocket Pharmaceuticals, Inc. (RCKTW) — 49 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 32 8-K, 6 10-Q, 5 SC 13G/A.
View Rocket Pharmaceuticals, Inc. on SEC EDGAR
Overview
Rocket Pharmaceuticals, Inc. (RCKTW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Rocket Pharmaceuticals, Inc. reported a net loss of $50,332 thousand for the three months ended September 30, 2025, an improvement from a net loss of $66,719 thousand in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $180,585 thousand, compared to $198,419 th
Sentiment Summary
Across 49 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 47 neutral. The dominant filing sentiment for Rocket Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Rocket Pharmaceuticals, Inc. (RCKTW) has filed 6 10-Q, 32 8-K, 2 DEF 14A, 2 10-K, 1 SC 13D/A, 5 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (49)
Risk Profile
Risk Assessment: Of RCKTW's 40 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 23 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$180,585 thousand |
| EPS | N/A |
| Debt-to-Equity | 0.17 |
| Cash Position | $75,948 thousand |
| Operating Margin | N/A |
| Total Assets | $368,033 thousand |
| Total Debt | $54,364 thousand |
Key Executives
- Jonathan Leff
- Sarah Kelly
- David Epstein
- Susan Miller
- Dr. Jonathan M. Rothberg
- Mr. David M. S. Kim
- RODERICK WONG, M.D.
- David M. Epstein
Industry Context
Rocket Pharmaceuticals operates in the highly competitive and capital-intensive biotechnology and pharmaceutical sector. This industry is characterized by long development cycles, high R&D costs, significant regulatory hurdles, and the potential for substantial returns upon successful drug commercialization. Companies like Rocket Pharmaceuticals often rely heavily on venture capital or public markets to fund their operations until they achieve profitability, if ever.
Top Tags
8-K (7) · 8-k (6) · financial-reporting (6) · filing (4) · management-change (4) · board-of-directors (3) · financials (3) · operations (3) · corporate-governance (3) · 10-Q (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $75,948 | Decreased from $163,635 thousand at December 31, 2024, to $75,948 thousand at September 30, 2025. |
| Net loss (9 months) | $180,585 | Net loss for the nine months ended September 30, 2025, compared to $198,419 thousand in 2024. |
| Net loss (3 months) | $50,332 | Net loss for the three months ended September 30, 2025, compared to $66,719 thousand in 2024. |
| Research and development expenses (9 months) | $112,668 | Decreased from $133,887 thousand in 2024 to $112,668 thousand in 2025. |
| Research and development expenses (3 months) | $34,068 | Decreased from $42,315 thousand in Q3 2024 to $34,068 thousand in Q3 2025. |
| Net cash used in operating activities (9 months) | $155,174 | Cash used in operating activities for the nine months ended September 30, 2025. |
| Common shares outstanding | 108,222,228 | As of October 31, 2025. |
| SEC File Number | 001-36829 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 04-3475813 | Tax identification number for the company. |
| Period End Date | 20240930 | Financial reporting period |
| Filing Date | 20241107 | Date the report was submitted |
| Reporting Period End | 2024-06-30 | Quarterly financial data |
| Reporting Period End Date | 2024-03-31 | Conformed period of report |
| SIC Code | 2834 | Standard Industrial Classification |
| Directors to be elected | 10 | Annual Meeting Agenda Item |
Forward-Looking Statements
- {"claim":"Rocket Pharmaceuticals' stock may experience increased stability due to Wellington Management Group LLP's significant institutional holding.","entity":"Rocket Pharmaceuticals, Inc.","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Rocket Pharmaceuticals, Inc. (RCKTW)?
Rocket Pharmaceuticals, Inc. has 49 recent SEC filings from Jan 2024 to Nov 2025, including 32 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RCKTW filings?
Across 49 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 47 neutral. The dominant sentiment is neutral.
Where can I find Rocket Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Rocket Pharmaceuticals, Inc. (RCKTW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Rocket Pharmaceuticals, Inc.?
Key financial highlights from Rocket Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RCKTW?
The investment thesis for RCKTW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Rocket Pharmaceuticals, Inc.?
Key executives identified across Rocket Pharmaceuticals, Inc.'s filings include Jonathan Leff, Sarah Kelly, David Epstein, Susan Miller, Dr. Jonathan M. Rothberg and 3 others.
What are the main risk factors for Rocket Pharmaceuticals, Inc. stock?
Of RCKTW's 40 assessed filings, 1 were flagged high-risk, 16 medium-risk, and 23 low-risk.
What are recent predictions and forward guidance from Rocket Pharmaceuticals, Inc.?
Recent forward-looking statements from Rocket Pharmaceuticals, Inc. include guidance on {"claim":"Rocket Pharmaceuticals' stock may experience increased stability due to Wellington Management Group LLP's sign.